Article
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
Leukemia & lymphoma - 1 Jan 2015
Lucas David M, Ruppert Amy S, Lozanski Gerard, Dewald Gordon W, Lozanski Arletta, Claus Rainer, Plass Christoph, Flinn Ian W, Neuberg Donna S, Paietta Elisabeth M, Bennett John M, Jelinek Diane F, Gribben John G, Hussein Mohamad A, Appelbaum Frederick R, Larson Richard A, Moore Dennis F, Tallman Martin S, Byrd John C, Grever Michael R
Abstract excerpt
Fludarabine (F) and cyclophosphamide (C) remain backbones of up-front chemotherapy regimens for chronic lymphocytic leukemia (CLL). We report long-term follow-up of a randomized F vs. FC trial in untreated CLL (#) . With median follow-up of 88 months, estimated median progression-free survival (PFS) was 19.3 vs. 48.1 months for F (n = 109) and FC (n = 118), respectively (p < 0.0001), and median overall survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.